Risk factors
Castle Biosciences (CSTL) risk factors
Item 1A of every Castle Biosciences Inc. 10-K on file, and what changed from one year to the next. Readings are automated and can be wrong; check the filing for the exact wording.
- FY2025 10-K risk factors76 risks5 new6 dropped14 reworded
Regulatory exposure broadened to FDA authorization, LDT legislation, QMSR, agency disruptions, tariffs and shifting government policy.
Filed Feb 26, 2026 - FY2024 10-K risk factors77 risks
Medicare and a commercial payor dominate revenue, contributing 47% and 15% respectively in 2024. Tests like DecisionDx-Melanoma and TissueCypher drive current financial performance. Growth relies heavily on securing reimbursement, clinician adoption, and navigating complex laboratory regulations.
Filed Feb 27, 2025